Ergul Ekiz Elif, Arslan Murat, Ozcan Mukaddes, Gultekin Guldal Inal, Gulay Ozlem Yildiz, Kirmizibayrak Turgut, Giger Urs
Department of Physiology, Faculty of Veterinary Medicine, Istanbul University, Avcilar, Istanbul, Turkey.
Department of Physiology, Faculty of Veterinary Medicine, Mehmet Akif Ersoy University, Bahcelievler, Burdur, Turkey.
Vet Clin Pathol. 2011 Dec;40(4):518-523. doi: 10.1111/j.1939-165X.2011.00370.x.
Dog erythrocyte antigen (DEA) 1.1 is the most important RBC antigen clinically, as it is highly immunogenic and causes acute hemolytic transfusion reactions (HTR) in sensitized dogs.
The aims of this study were to determine the frequency of DEA 1.1 expression in 4 Turkish dog breeds, and to estimate the potential risk of HTR when blood from a DEA 1.1-positive donor is administered to a DEA 1.1-negative recipient following sensitization by a prior mismatched transfusion.
EDTA blood samples (n = 178) were typed for DEA 1.1 using a commercial gel-column agglutination test (ID-Gel-Test Canine DEA 1.1). Probabilities of sensitization and risk of an HTR were calculated.
The frequency of positivity for DEA 1.1 among Kars (n = 59), Kangal (n = 53), Akbash (n = 50), and Catalburun (n = 16) breeds was 71.2%, 67.9%, 60.0%, and 50.0%, respectively. Potential risk for occurrence of an HTR after administration of blood from a dog of the same breed ranged from 12.5% to 14.8%, whereas HTR induced by blood of a dog from a different breed ranged from 7.2% to 25.3%.
The frequency of DEA 1.1-positive dogs among 4 Turkish breeds is high compared with that of most other breeds previously surveyed. The predicted risk of both sensitization and occurrence of DEA 1.1-related HTR following transfusion between dogs of either the same or different Turkish breeds was considerable. Although few dogs are transfused ≥4 days after the first transfusion, we recommend that (1) all donors and recipients be typed for DEA 1.1, (2) DEA 1.1-negative recipients receive only DEA 1.1-negative blood, and (3) blood be cross-matched prior to transfusing any dog ≥4 days after the first transfusion. These guidelines are also applicable to other breeds and countries.
犬红细胞抗原（DEA）1.1是临床上最重要的红细胞抗原，因为它具有高度免疫原性，可在致敏犬中引发急性溶血性输血反应（HTR）。
本研究的目的是确定4个土耳其犬种中DEA 1.1表达的频率，并评估在先前不匹配输血致敏后，将DEA 1.1阳性供体的血液输给DEA 1.1阴性受体时发生HTR的潜在风险。
使用商业凝胶柱凝集试验（ID-Gel-Test Canine DEA 1.1）对178份乙二胺四乙酸（EDTA）血样进行DEA 1.1分型。计算致敏概率和HTR风险。
在卡尔斯犬（n = 59）、坎加尔犬（n = 53）、阿克巴什犬（n = 50）和卡特布尔伦犬（n = 16）品种中，DEA 1.1阳性的频率分别为71.2%、67.9%、60.0%和50.0%。同一品种犬输血后发生HTR的潜在风险为12.5%至14.8%，而异品种犬血液诱导的HTR风险为7.2%至25.3%。
与之前调查的大多数其他品种相比，4个土耳其品种中DEA 1.1阳性犬的频率较高。在土耳其同一品种或不同品种犬之间输血后，致敏和发生DEA 1.1相关HTR的预测风险相当高。尽管很少有犬在首次输血后≥4天接受输血，但我们建议：（1）所有供体和受体都进行DEA 1.1分型；（2）DEA 1.1阴性受体仅接受DEA 1.1阴性血液；（3）在首次输血后≥4天给任何犬输血前进行交叉配血。这些指南也适用于其他品种和国家。
